Proteomic analysis of laser microdissected melanoma cells from skin organ cultures.
Gaining insights into the molecular events that govern the progression from melanoma in situ to advanced melanoma and understanding how the local microenvironment at the melanoma site influences this progression are two clinically pivotal aspects that to date are largely unexplored. In an effort to identify key regulators of the crosstalk between melanoma cells and the melanoma-skin microenvironment, primary and metastatic human melanoma cells were seeded into skin organ cultures (SOCs) and grown for two weeks. Melanoma cells were recovered from SOCs by laser microdissection and whole-cell tryptic digests were analyzed by nanoflow liquid chromatography-tandem mass spectrometry. The differential protein abundances were calculated by spectral counting, the results of which provides evidence that cell-matrix and cell-adhesion molecules that are upregulated in the presence of these melanoma cells recapitulate proteomic data obtained from comparative analysis of human biopsies of invasive melanoma and a tissue sample of adjacent, noninvolved skin. This concordance demonstrates the value of SOCs for conducting proteomic investigations of the melanoma microenvironment.
Hood
Brian L
BL
Department of Pharmacology & Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh, PA, USA.
Grahovac
Jelena
J
Flint
Melanie S
MS
Sun
Mai
M
Charro
Nuno
N
Becker
Dorothea
D
Wells
Alan
A
Conrads
Thomas P
TP
D000185:Actinin / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008545:Melanoma / Q000378:metabolism*; D042282:Microdissection; D040901:Proteomics / Q000379:methods*; D012867:Skin / Q000166:cytology; D053719:Tandem Mass Spectrometry; D019063:Tenascin / Q000378:metabolism; D046509:Tissue Culture Techniques / Q000379:methods*; D014407:Tumor Cells, Cultured / Q000378:metabolism*
C111453:ACTN4 protein, human; D019063:Tenascin; D000185:Actinin
J Proteome Res. 2009 May;8(5):2501-10
19222175
J Biol Chem. 2010 Jan 22;285(4):2591-600
19920151
J Cancer Res Clin Oncol. 2009 Sep;135(9):1257-64
19288131
Z Naturforsch B. 1970 Mar;25(3):332-3
4392802
J Cell Commun Signal. 2009 Dec;3(3-4):189-200
19798599
Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58
15036264
Am Fam Physician. 1989 May;39(5):203-14
2655407
Clin Cancer Res. 2008 Feb 15;14(4):1002-14
18281532
Eur J Cancer. 2008 Dec;44(18):2760-5
19026532
Clin Exp Metastasis. 2003;20(8):685-700
14713103
J Cell Physiol. 2008 Feb;214(2):504-12
17708541
Histopathology. 2004 Oct;45(4):405-11
15469480
Nat Methods. 2007 Mar;4(3):207-14
17327847
Cancer Sci. 2010 Feb;101(2):523-9
19930159
J Clin Invest. 2001 Apr;107(8):929-34
11306593
Dev Dyn. 2000 Jun;218(2):235-59
10842355
Br J Dermatol. 2000 Feb;142(2):210-22
10730751
Cancer Res. 2001 Jun 1;61(11):4642-3
11389102
Biochim Biophys Acta. 2009 Feb;1794(2):159-67
18996230
Crit Rev Biochem Mol Biol. 1989;24(1):41-67
2667895
Cancer Microenviron. 2008 Dec;1(1):93-102
19308688
BMC Med Genomics. 2008 Apr 28;1:13
18442402
J Med. 2004;35(1-6):141-9
18084872
PLoS One. 2009;4(4):e5199
19381273
J Pathol. 2006 Oct;210(2):181-91
16924594
Pigment Cell Res. 2000;13 Suppl 8:68-72
11041360
Proteomics. 2008 Nov;8(22):4733-47
18942674
J Cell Biol. 1996 Nov;135(4):991-1007
8922382
Cell Mol Life Sci. 2008 Sep;65(17):2688-701
18488141
Nature. 1996 Feb 1;379(6564):466-9
8559255
Methods Mol Biol. 2005;289:61-70
15502170
Cancer Res. 1995 Oct 1;55(19):4283-6
7671236
Anal Chem. 2004 Jul 15;76(14):4193-201
15253663
J Invest Dermatol. 2001 Nov;117(5):1042-9
11710911
Am J Pathol. 2000 Jan;156(1):193-200
10623667
J Invest Dermatol. 1991 Jul;97(1):20-6
2056188
J Gastrointest Surg. 2009 Nov;13(11):1948-54; discussion 1954
19760374
J Cancer Res Clin Oncol. 2008 Nov;134(11):1219-27
18446369